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OBJECTIVES The goal of this study was to compare myocardial perfusion reserve (MPR) before and after
long-term treatment with lisinopril and losartan in patients with hypertension and left
ventricular hypertrophy (LVH).
BACKGROUND Studies have suggested that treatment with angiotensin-converting enzyme inhibitors
(ACEIs) improves MPR in patients with hypertension by potentiating endogenous brady-
kinins. Because angiotensin receptor blockers (ARBs) lack a direct effect on bradykinins, we
hypothesized that they may not improve MPR.
METHODS We measured pre- and post-treatment myocardial blood flow (MBF) by positron emission
tomography in 17 patients (lisinopril: 9 patients, losartan: 8 patients) with hypertension and
LVH at baseline and after coronary vasodilation with intravenous dipyridamole. In addition,
we measured rest and hyperemic blood flow in eight normotensive controls.
RESULTS Post-treatment maximal coronary blood flow and MPR in the lisinopril group increased
significantly compared with pretreatment values (3.5 1.2 vs. 2.6 1.1 ml/min/g, p 0.02;
3.7  1.1 vs. 2.4  1 ml/min/g, respectively, p  0.002, respectively). Post-treatment
hyperemic flow in the patients treated with lisinopril was not significantly different from
corresponding measurements in controls (3.5  1.2 vs. 3.9  1 ml/min/g, respectively, p 
NS). In the patients treated with losartan, there was no difference between pre- and
post-treatment MBF values and MPR.
CONCLUSIONS Myocardial perfusion reserve and maximal coronary flow improved in asymptomatic patients
with hypertension-induced LVH after long-term treatment with lisinopril but not with
losartan. Thus, ACEIs, but not ARBs, might be effective in repairing the coronary
microangiopathy associated with hypertension-induced LVH. (J Am Coll Cardiol 2002;40:
703–9) © 2002 by the American College of Cardiology Foundation
Left ventricular hypertrophy (LVH) is a major predictor of
cardiovascular mortality and morbidity independent of
blood pressure level (1,2). Impaired myocardial perfusion
reserve (MPR) is believed to play a role in the cardiovascular
mortality and morbidity associated with hypertension-
induced LVH (1). Long-term treatment with angiotensin-
converting enzyme inhibitors (ACEIs) has been shown to
improve MPR in patients with hypertension and clinical
signs of ischemia but without angiographic evidence of
epicardial coronary artery disease (2). However, it is not
clearly known if these findings can be extrapolated to
asymptomatic patients with hypertension-induced LVH.
Several studies have shown that the improvement in
MPR by ACEIs is mediated by potentiation of endogenous
bradykinin (3–6). Because angiotensin-receptor blockers
(ARBs) do not directly potentiate endogenous bradykinin, they
may not have the same effect on myocardial perfusion as
ACEI.
Thus, the aim of this study was to compare MPR before
and after long-term treatment with an ACEI, lisinopril and
an ARB, losartan, in patients with moderate hypertension
and LVH. We also sought to examine if treatment with
angiotensin antagonists will normalize MPR by comparing
post-treatment measurements in the patients with the MPR
in normotensive controls.
METHODS
Patient population. The Institutional Review Board of
Columbia University approved the study. Informed consent
was obtained. Participants with pre-existing hypertension
and LVH (left ventricular [LV] mass  125 g/m2) and
normotensive controls were recruited from the patient
population at New York Presbyterian Medical Center in
New York City and the surrounding community. Pre-
existing hypertension was validated by blood pressure mea-
surement on entry. Race/ethnicity was based on self-report.
Exclusion criteria for patients with hypertension and
LVH included: echocardiographic evidence of significant
cardiac abnormality other than hypertrophy, such as valvular
heart disease, LV systolic dysfunction, and wall motion
abnormalities; significant cardiovascular disease other than
hypertension with LVH; history of chest pain; pregnancy;
malignant, accelerated, or secondary hypertension; broncho-
spastic lung disease; regional differences in MPR on pre-
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treatment positron emission tomography (PET) studies
suggestive of coronary artery disease; diabetes mellitus; smok-
ing; renal failure; secondary hypertension and prior treatment
with angiotensin antagonists. Additional exclusion criteria for
normotensive controls included hypertension and LVH.
Using these criteria we recruited 20 patients, including 14
African Americans and six Latinos with hypertension-
induced LVH and 8 normotensive controls. Blood was tested
for occult diabetes mellitus, renal failure, and hyperlipidemia.
Measurement of MPR. Absolute myocardial blood flow
(MBF) was measured at rest by PET and after maximal
coronary vasodilation with intravenous dipyridamole using
15O-water as the flow tracer. All medications were held for
at least five half-lives before the PET studies. Measurement
of MBF by PET was performed on an ECAT EXACT-47
PET scanner (Siemens, Iselin, New Jersey), which provides
47 contiguous transaxial slices and has a postprocessing
spatial resolution of 9 to 10 mm in plane and 4 to 5 mm in
the axial direction.
The subjects were studied after an overnight fast and
abstinence from methyl xanthines including caffeine for
24 h. Subjects were placed supine in the PET scanner. The
localization of the heart within the axial field of view of the
scanner was confirmed by performing a 2-min “positioning”
scan using a rotating 68Ge/68Ga-rod source. Patient posi-
tioning was marked using laser cross beams and ink marks
on the patient’s torso. A 20-min transmission scan with the
rotating 68Ge/68Ga-rod source was performed to generate
an attenuation correction map for the correction of the
emission sinogram.
A bolus administration of 0.20 mCi/kg of 15O-water was
given with simultaneous initiation of dynamic data acquisi-
tion for 300 s. After completion of the rest perfusion scans,
0.56 mg/kg of dipyridamole was administered over 4 min.
An additional 4 min was allowed to achieve peak flow
response, and 0.20 mCi/kg of 15O-water was readminis-
tered. Dynamic data acquisition was initiated for 300 s. The
initial 20 s of the two dynamic datasets were summed to
identify the blood pool phase. The emission sinograms were
corrected for radioactivity decay, reconstructed into trans-
axial slices and reoriented into short-axis tomograms. Each
of the short-axis tomograms was divided into four equal
myocardial sectors and count data in each sector used to
generate myocardial tissue time activity curves. The arterial
input function was obtained from the time-activity curve
generated from a 1.5-cm3 region-of-interest placed in the
center of basal short-axis tomograms. Regional MBF was
quantified using a one-compartment model (7–9). This
parameter-optimization approach incorporates corrections
for both partial volume effects and blood to myocardial
spillover. As no regional differences were noted, regional
MBF values were averaged to yield one global flow value for
each patient at rest and after coronary vasodilation. Myo-
cardial perfusion reserve was expressed as the ratio of global
maximal to resting absolute flow values.
Measurement of LV mass. An LV mass of 125 g/m2 by
M-mode echocardiography was used as an inclusion crite-
rion for the patients and an exclusion criterion for the
controls (1). Because of lower measurement variability, we
measured baseline and post-treatment LV mass by three-
dimensional echocardiography (10,11).
Measurement of LV mass by M-mode echocardiography.
Two-dimensional guided M-mode echocardiography was
performed to measure LV wall mass. The ultrasound beam
was aligned perpendicularly to the interventricular septum
and the LV posterior wall at a level slightly below the mitral
leaflet tips. Left ventricular mass was calculated from
measurements of the septal (SD) and posterior wall thick-
ness (PD) and left ventricular dimensions (LVID) at end-
diastole using the cube formula: 1.05  ([SD  LVID 
PD]3  [LVID]3) (12).
Measurement of LV mass by three-dimensional echocar-
diography. The three-dimensional echocardiographic sys-
tem (K3 Systems, Inc., Darien, Connecticut) comprises an
acoustic spatial locater (Model GP 8-3D, Science Accesso-
ries Corp., Stratford, Connecticut), and personal computer
(Model 4DX-33V, Gateway 2000, North Sioux City, South
Dakota) (13,14). These components are linked to a conven-
tional two-dimensional echocardiograph interfaced with an
acoustic spatial locater. Left ventricular volume is computed
from a series of guided six to eight real-time parasternal
short-axis images. These images were stored along with
their XYZ Cartesian coordinates in the personal computer.
End-diastolic video frames from each acquired cine-loop were
selected for off-line endocardial and epicardial boundary trac-
ing. Epicardial and endocardial volumes were determined from
their corresponding boundaries using a polyhedral surface
reconstruction algorithm. Endocardial volume was subtracted
from epicardial volume to yield myocardial volume, which was
multiplied by myocardial density to yield LV mass.
Treatment plan. After completing the baseline studies, the
patients were randomized to treatment with either lisinopril
or losartan. The starting doses for lisinopril and losartan
were 10 mg and 50 mg, respectively. The patients were seen
weekly, and their medications were adjusted until either a
blood pressure of 140/90 mm Hg or less or the maximal
daily dosage of the medication was attained. Hydrochlo-
rothiazide (up to 25 mg daily) and atenolol (up to 100 mg
daily) were added as needed for further blood pressure
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
ARB  angiotensin-receptor blocker
LV  left ventricular
LVH  left ventricular hypertrophy
LVID  left ventricular dimensions
MBF  myocardial blood flow
MPR  myocardial perfusion reserve
PD  posterior wall thickness
PET  positron emission tomography
SD  septal wall thickness
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control. After a blood pressure of 140/90 mm Hg or less was
attained, patients were followed monthly thereafter for the
duration of the study.
Seventeen patients completed the study. Two patients
declined the follow-up PET study, and one patient was lost
to follow-up. After approximately one year of blood pressure
control, resting and hyperemic absolute MBF in the 17
patients was measured by PET, using the same dose of
dipyridamole as was used in the pretreatment study. We also
used the same dose of 15O-water for the rest and hyperemic
flow measurements as was used in the pretreatment studies.
We withdrew all antihypertensives for at least five half-lives
before the post-treatment studies to minimize the acute
affects of the medications on coronary blood flow. The
patients had their blood pressures measured daily during
this washout phase.
Statistical analysis. Absolute rest and hyperemic flow and
MPR were compared before and after treatment using
paired t test analysis. Analysis of variance with Bonferroni
correction was used to test for differences in continuous
variables between groups. Categorical data were compared
using chi-square analysis. A p value of 0.05 was consid-
ered significant for all analyses.
RESULTS
Demographic distribution. The two treatment arms were
comparable in terms of race and gender distribution. There
were more whites in the control group and more African
Americans in the patient groups. The duration of hyper-
tension is not different between the two groups (Table 1).
The number of patients who required cotreatment with
diuretics and beta-blockers were equal between the two
treatment groups (Table 1). Expectedly, pretreatment blood
pressure and LV mass were higher in the patients than in
the controls (Table 2).
Change in blood pressure. Blood pressure control was
achieved for a mean duration of 11 1 months. The change
in mean arterial pressure over the treatment period was not
significantly different between the two treatment groups
(Table 2). The mean doses of lisinopril and losartan that
were used were 35  10 mg and 90  10 mg, respectively.
Pretreatment systolic and diastolic blood pressures were
similar in the two patient groups and higher than corre-
sponding measurements in controls. On-treatment systolic
and diastolic blood pressure measurements were also higher
than measurements in controls (Table 2).
The baseline blood pressure (after drug wash-out) at the
time of the post-treatment PET study was neither different
between the two groups nor different from the pretreatment
blood pressure in both groups. The frequency of cotreat-
ment with diuretics or beta-blockers and their dosages were
not significantly different between the two treatment groups
(Table 1).
Hemodynamic response to dipyridamole administration.
The response to dipyridamole infusion was not significantly
different between the two treatment groups. During the
pretreatment PET studies, heart rate increased and systolic
blood pressure decreased by 18  4 beats/min and 8  2 mm
Hg, respectively, with dipyridamole infusion. The response to
dipyridamole during the post-treatment PET study was sim-
ilar; heart rate increased and blood pressures decreased by 14
3 beats/min and 6  2 mm Hg, respectively.
Table 1. Subject Characteristics
Controls
(n  8)
Lisinopril Group
(n  9)
Losartan Group
(n  8)
Lisinopril vs.
Losartan (p)
Age (yrs) 55  9 55  2 43  4 NS
Women (n, %) 5 4 5 NS
Duration of hypertension 6  1 4  2 NS
African American (n) 0 6 6
Latino (n) 3 3 2
White 5 0 0
Body mass index (kg/m2) 25  2 32  5 34  3 NS
Total cholesterol (mg/dl) 185  12 178  11 182  7 NS
Treatment with diuretics
(dose in mg)
7 (25) 6 (25) NS
Treatment with atenolol
(dose in mg)
6 (50) 5 (75) NS
Table 2. Clinical Characteristics
Controls
Lisinopril Group Losartan Group
Pretreatment On-Treatment Pretreatment On-Treatment
SBP (mm Hg) 120  15 160  16 136  10 167  20 137  15
DBP (mm Hg) 67  9 93  16 87  5 92  14 84  12
LV mass (g) 124  27 211  56 202  44 199  23 189  24
HR (beats/min) 66  5 83  8 78  7 92  14 74  12
DBP  diastolic blood pressure; HR  heart rate; LV  left ventricular; SBP  systolic blood pressure.
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Change in LV mass. Pre- and post-treatment LV mass
were significantly higher in the patients compared with
corresponding measurements in controls. Left ventricular
mass decreased by 4% in the lisinopril group and by 5% in
the losartan group. The change in LV mass was neither
significant in either group nor different between the two
groups (Table 2). There was no relationship between the
magnitude of change in LV mass and the change in systolic
or diastolic blood pressure over the treatment period.
Change in absolute MBF in patients versus controls.
Pretreatment resting blood flow was not significantly dif-
ferent between patients and controls (1.1  0.4 vs. 1  0.2,
respectively). Pretreatment hyperemic flow was significantly
lower in the patients than in the controls (2.8  0.9 vs. 3.9
 1 ml/g/min, p  0.01) but not different between the two
treatment groups 2.6  1.1 vs. 2.9  0.5, lisinopril vs.
losartan, respectively). Pre- and post-treatment resting flow
values in the combined patient population were not signif-
icantly different (1.1  0.2 vs. 0.9  0.2, respectively).
Although post-treatment hyperemic flow in the combined
patient population was not significantly different from baseline
values (3.2  1.1 vs. 2.8  0.9 ml/min/g, respectively), post
treatment flow reserve improved significantly from 2.8  0.8
pretreatment to 3.4  0.8 post-treatment (p  0.04).
Change in absolute MBF in the lisinopril versus losartan
arms. Post treatment resting flow was not different from
pretreatment flow values in both patient groups (Figs. 1a
and 2a). However, in the lisinopril group, post-treatment
hyperemic flow increased significantly compared with pre-
treatment hyperemic flow (3.5  1.2 vs. 2.6  1.1 ml/
min/g, p  0.02) (Fig. 1b). Consequently, MPR in the
lisinopril group increased significantly after treatment com-
pared with pretreatment values (3.7  1.1 vs. 2.4  1,
respectively, p  0.002) (Fig. 1c). Post-treatment hyper-
emic flow in the patients treated with lisinopril was not
significantly different from corresponding measurements in
controls (Fig. 3). In the patients treated with losartan,
posttreatment absolute MBF and MPR did not change
compared with pretreatment values (Figs. 2b and 2c), and
post-treatment hyperemic flow remained significantly lower
than corresponding measurements in controls (Fig. 3).
There was no correlation between the change in absolute
MBF and the extent of LV mass regression. Furthermore,
the change in absolute MBF did not correlate with the
magnitude of the reduction in mean arterial pressure.
DISCUSSION
Myocardial perfusion reserve increased significantly in the
group of patients as a whole after treatment compared with
baseline values. However, absolute hyperemic flow did not
change significantly from baseline. This would suggest that
absolute vasodilatory capacity did not improve in the group
as a whole compared with baseline. However, when the
lisinopril and losartan treatment arms were analyzed sepa-
rately, we found an improvement in both MPR and absolute
hyperemic flow in the lisinopril group. However, in the
losartan group, neither MPR nor absolute hyperemic flow
changed significantly from baseline. Furthermore, post-
treatment hyperemic flow in the group treated with lisino-
pril was not different from corresponding measurements in
controls (Fig. 3). Thus, treatment with lisinopril resulted in
normalization of MPR in this group of patients.
The fact that maximal myocardial perfusion improved in
the patients that were treated with a lisinopril-based regi-
men and was unchanged in those that were treated with a
losartan-based regimen suggests that the improvement in
maximal MBF might be unrelated to the direct effects of
lisinopril on angiotensin II production. Because the
angiotensin-converting enzyme plays a major role in the
breakdown of kinins, a mechanism for the improvement in
myocardial perfusion by lisinopril might be the effect of
increased availability of bradykinin (5) and, consequently,
vasodilatory prostaglandins, and nitric oxide. Unlike ACEIs,
ARBs do not have any direct effect on kinin metabolism.
Because lisinopril was withdrawn for at least five half-
lives and blood pressure rose to pretreatment levels before
the post-treatment flow measurements were taken, it is
unlikely that the observed improvement in hyperemic MBF
and MPR could be due to an acute effect of the drug,
although the latter cannot be completely excluded. Further-
more, the improvement in MPR despite the absence of a
significant reduction in LV mass suggests that the improve-
ment in coronary vasodilatory capacity might not be attrib-
utable to a reduction in extravascular compressive forces on
the coronary microvasculature.
A potential mechanism for the improvement in maximal
myocardial perfusion is an increase in myocardial capillary
density (15,16). Several studies have demonstrated an im-
provement in MBF in hypertensive animals; however, the
results of such studies in humans have yielded conflicting
results. Canby et al. (15) demonstrated increased capillary
density and decreased minimal coronary vascular resistance in
captopril-treated spontaneously hypertensive rats compared
with untreated controls. Normalization of medial wall thick-
ness and minimal coronary resistance were also found in
14-week old spontaneously hypertensive rats after a 12-week
treatment with lisinopril compared with untreated controls.
Goehlke et al. (5) demonstrated an improvement in
myocardial capillary density in spontaneously hypertensive
rats after treatment with lisinopril. However, in the same
study the investigators showed that the improvement in
myocardial capillary density was abolished when the rats
were pretreated with bradykinin B2 receptor antagonist,
icatibant. Motz et al. (4) demonstrated a 43% improvement
in maximal coronary blood flow and a 23% reduction in
minimal coronary vascular resistance in 15 patients with
hypertension, LVH, clinical evidence of myocardial isch-
emia with normal coronary angiograms after treatment with
enalapril for one year. Parodi et al. (17) found an improve-
ment in MPR, measured by PET with 13-NH3 in 10
patients treated with verapamil, while another group of 10
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patients that were treated with enalapril did not show any
significant change. The majority of the studies on the effects
of angiotensin antagonists on myocardial perfusion in pa-
tients with hypertension-induced LVH were conducted in
patients with clinical symptoms of myocardial ischemia (4,18).
To the best of our knowledge, ours is the first study to compare
the effects of ARBs and ACEIs in an asymptomatic population
of patients with moderate hypertension and LVH.
It is also noteworthy that the majority of our patients are
African Americans (70%). Some studies have suggested that
Figure 1. (a) Pre- and post-treatment resting flow values in patients treated with angiotensin-converting enzyme inhibitors (ACEIs). (b) Pre- and
post-treatment maximal flow values in patients treated with ACEIs. (c) Pre- and post-treatment myocardial perfusion reserve in patients treated with
ACEIs.
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African Americans with hypertension or heart failure may
not benefit from treatment with ACEIs (19,20). However,
we found a significant improvement in MPR and maximal
MBF in the African Americans that we studied.
Study limitations. The limitations of this study should be
recognized. First, the sample size is not large, and there is
significant interpatient variability in the change in absolute
MBF after treatment. Thus, further studies in larger pop-
ulations are needed. Second, despite adequate blood pres-
sure control for a mean duration of 11 months, we did not
achieve a significant reduction in LV mass. However, the
absolute reduction in LV mass in our study population is
Figure 2. (a) Pre- and post-treatment resting flow values in patients treated with angiotensin-receptor blockers (ARBs). (b) Pre- and post-treatment
maximal flow values in patients treated with ARBs. (c) Pre- and post-treatment myocardial perfusion reserve in patients treated with ARBs.
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close to what was observed in some large-scale clinical trials
of LV mass regression with antihypertensive treatment.
Furthermore, the study was not powered from the outset to
detect statistically significant changes in LV mass. It is
possible that absence of LV mass regression might have
contributed to the failure of the ARB group to improve their
maximal MBF with treatment. However, we observed an
improvement in absolute MBF in the ACEI group without
a significant change in LV mass.
In addition, the difference in race between patients and
controls is unlikely to have influenced our findings because
race has not been shown to have an independent effect on
coronary blood flow (21).
Conclusions. Our study shows that MPR and maximal
coronary flow improved in asymptomatic patients with
hypertension-induced LVH after long-term treatment with
lisinopril but not with losartan. Thus, ACEIs but not ARBs
might be effective in repairing the coronary microangiopa-
thy associated with hypertension-induced LVH.
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